By Denny Jacob
AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint.
Shares were recently trading around $17. The stock is down about 44% over the last year.
AnaptysBio said the phase 2b study of rosnilimab in patients with moderate-to-severe rheumatoid arthritis on background conventional disease-modifying antirheumatic drugs met its main goal of lowering disease activity at week 12 in all three doses of the drug.
The clinical stage biotechnology company said rosnilimab achieved statistical significance in at least one dose and numerical superiority at all doses on key secondary endpoints at week 12, even though higher than typical placebo rates were observed.
AnaptysBio added that data across all doses showed immunological impact with robust on-target pharmacological activity in patients under treatment that was not observed for those on placebo.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 12, 2025 08:21 ET (13:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。